



Please use a plus sign (+) inside this box →



06-28-04

IFW

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/692,071
		Filing Date	October 22, 2003
		First Named Inventor	KOBILKA, BRIAN K.
		Group Art Unit	1653
		Examiner Name	Not yet assigned
Total Number of Pages in This Submission	7	Attorney Docket Number	STAN-213CIP
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): POSTCARD	
<input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement SB08A Form <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36.513 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	June 24, 2004		

EXPRESS MAIL LABEL NO. EV333997499 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. **EV333997499 US**

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	STAN-213CIP
	First Named Inventor	KOBILKA, BRIAN K.
	Application Number	10/692,071
	Confirmation No.	8423
	Filing Date	October 22, 2003
	Group Art Unit	1653
	Examiner Name	Not yet assigned
Title: "CONFORMATIONAL ASSAYS TO DETECT BINDING TO MEMBRANE SPANNING, SIGNAL- TRANSDUCING PROTEINS"		

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent application serial number 09/935,061 filed 8/21/2001 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-213CIP may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 24, 2004

By: 

Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/692,071	
			Filing Date	October 22, 2003	
			First Named Inventor	KOBILKA, BRIAN K.	
			Art Unit	1653	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	5	Attorney Docket Number	STAN-213CIP

U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials [*]	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ALTENBACH, et al. "Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: A site-directed spin-labeling study", <i>Biochemistry</i> Vol. 35(38): 12470-12478 (1996).	
		ARINS, et al. "A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin", <i>J. Biol. Chem.</i> Vol. 269: 23879-23881 (1994).	
		BERTIN, et al. "Cellular Signaling by an Agonist-activated receptor/Gsa Fusion Protein", <i>Proc. Natl. Acad. Sci. USA</i> , (1994) Vol. 91: 8827-8831.	
		BOND, et al. "Do Recent Operational Studies Indicate That a Single State Model Is No Longer Applicable to G Protein-Coupled Receptors?", <i>Annals of New York Acad. Sci.</i> , (1997) Vol. 812: 92-97.	
		CHIDIAC, et al. "Agonist-induced modulation of Inverse Agonist Efficacy at the β_2 -Adrenergic Receptor", <i>Molecular Pharmacology</i> , 50: 662-669 (1996).	
		DUNHAM, et al. "Conformational changes in rhodopsin", <i>J. Biol. Chem.</i> Vol. 274: 1683-1690 (1999).	
		FARAHBAKHS, et al. "Photoactivated conformational changes in rhodopsin: A time-resolved spin label study", <i>Science</i> Vol. 262: 1416-1419 (1993).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <div style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div style="text-align: center; font-size: small;">(use as many sheets as necessary)</div>			Complete if Known		
			Application Number	10/692,071	
			Filing Date	October 22, 2003	
			First Named Inventor	KOBILKA, BRIAN K.	
			Group Art Unit	1653	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	5	Attorney Docket Number	STAN-213CIP

		FARRENS, et al. "Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin", <i>Science</i> Vol. 274(5288): 768-770 (1996).	
		FRAUENFELDER, et al. "The energy landscapes and motions of proteins", <i>Science</i> Vol. 254: 1598-1603 (1991).	
		FREIRE. "Can allosteric regulation be predicted from structure?", <i>PNAS</i> Vol. 97(22): 11680-11682 (2000).	
		GETHER, et al. "Fluorescent Labeling of Purified β_2 Adrenergic Receptor", <i>Biochem.</i> , (1996) Vol. 35: 14040-14046.	
		GETHER, et al. "Agonists induce Conformational Changes in Transmembrane Domains III and VI of the β_2 Adrenoceptor", <i>The EMBO Journal</i> Vol. 16 No.22 pgs 6737-6747 (1994).	
		GETHER, et al. "Fluorescent labeling of purified β_2 adrenergic receptor", <i>J. Biol. Chem.</i> Vol. 270(47): 28268-28275 (1995).	
		GETHER, et al. "Agonists induce conformational changes in transmembrane domains III and VI of the β_2 receptor", <i>EMBO J.</i> Vol. 16(22): 6737-6747 (1997).	
		GHANOUNI, et al. "The effect of pH on β_2 adrenoceptor function", <i>J. Biol. Chem.</i> Vol. 275: 3121-3127 (2000).	
		GHANOUNI, et al. "Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor", <i>Proc. Natl. Acad. Sci. USA</i> , (2001) Vol. 98(11): 5997-6002.	
		GHANOUNI, et al. "Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor", <i>J. Biol. Chem.</i> , (2001) Vol. 276(27): 24433-24436.	
		GILMAN. "G Proteins: transducers of receptor-generated signals", <i>Annu. Rev. Biochem.</i> Vol. 56: 615-649 (1987).	
		GINTY. "Calcium regulation of gene expression: Isn't that spatial?", <i>Neuron</i> Vol. 18: 183-186 (1997).	
		GUDERMANN, et al. "Functional and structural complexity of signal transduction via G Protein-coupled receptors", <i>Annu. Rev. Neurosci.</i> Vol. 20: 399-427 (1997).	
		HAMM. "The many faces of G-Protein signaling", <i>The Journal of Biological Chemistry</i> Vol. 273: 669-672 (1998).	
		HOPKINSON, et al. "Non-Competitive Antagonism of β_2 -Agonist-Mediated Cyclic AMP Accumulation by ICI 118551 in BC3H1 Cells Endogenously Expressing Constitutively Active β_2 -Adrenoceptors", <i>British Journal of Pharmacology</i> , 131: 124-130 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/692,071
		Filing Date	October 22, 2003
		First Named Inventor	KOBILKA, BRIAN K.
		Group Art Unit	1653
		Examiner Name	Not Yet Assigned
Sheet	3	of	5
		Attorney Docket Number	STAN-213CIP

		HOSHI, et al. "Shaker Potassium channel gating I: Transitions near the open state", J. Gen. Physiol. Vol. 103(2): 249-278 (1994).	
		JENSEN, et al. "Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling", J. Biol. Chem., (2001) Vol. 276(12): 9279-9290.	
		JL, et al. "G-Protein coupled receptors", The Journal of Biological Chemistry Vol. 273: 17229-17302 (1998).	
		KENAKIN. "The classification of seven transmembrane receptors in recombinant expression systems", Pharmacological Review Vol. 48: 413-463 (1996).	
		KENAKIN. "Agonist-specific receptor conformations", Trends Pharmacol. Sci. Vol. 18(11): 416-417 (1997).	
		KOBILKA. "The role of cytosolic and membrane factors in processing of the human β -2 adrenergic receptor following translocation and glycosylation in a cell-free system", J. Biol. Chem. Vol. 265(13): 7610-7618 (1990).	
		KOBILKA. "Amino and carboxyl terminal modifications to facilitate the production and purification of a G-Protein-coupled receptor", Anal. Biochem. Vol. 231(1): 269-271 (1995).	
		KRUMINS, et al. "The stability of the agonist β_2 -Adrenergic receptor- G_s complex: Evidence for agonist-specific states", Mol. Pharmacol. Vol. 52(1): 144-154 (1997).	
		LEE, et al. "Restricting the mobility of $G_{s\alpha}$: Impact on receptor and effector coupling", Biochemistry Vol. 38: 13801-13809 (1999).	
		LEFF. "The two-state model of receptor activation", TiPS Vol. 16: 89-97 (1995).	
		LEFKOWITZ, et al. "Adenylate cyclase-coupled beta-adrenergic receptors: Structure and mechanisms of activation and desensitization", Ann. Rev. Biochem. Vol. 52: 159-186 (1983).	
		LEFKOWITZ, et al. "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins", TiPS Vol. 14: 304-307 (1993).	
		MATKO, et al. "Luminescence quenching by nitroxide spin labels in aqueous solution: Studies on the mechanism of quenching", Biochemistry Vol. 31: 703-711 (1992).	
		PALCZEWSKI, et al. "Crystal structure of rhodopsin: A G-Protein-coupled receptor", Science Vol. 289: 739-745 (2000).	
		PAROLA, et al. "Site-specific fluorescence labeling of the β_2 adrenergic receptor amino terminus", Anal. Biochem. Vol. 254: 88-95 (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/692,071		
		Filing Date	October 22, 2003		
		First Named Inventor	KOBILKA, BRIAN K.		
		Group Art Unit	1653		
		Examiner Name	Not Yet Assigned		
Sheet	4	of	5	Attorney Docket Number	STAN-213CIP

	PEREZ, et al. "Constitutive activation of a single effector pathway: Evidence for multiple activation states of a G Protein-coupled receptor", Mol. Pharmacol. Vol. 49(1): 112-122 (1996).	
	PETER MOMBAERTS "Seven-Transmembrane Proteins as Odorant and Chemosensory Receptors", Science Vol. 286 (1999) pgs 707-711.	
	REMMERS, et al. "Partial G Protein Activation by Fluorescent Guanine Nucleotide Analogs", The Journal of Biological Chemistry, (1996) Vol. 271, No. 9: pgs 4791-4797.	
	SAKMAR. "Rhodopsin: A prototypical G-Protein-coupled receptor", Progress in Nucleic Acid Research and Molecular Biology Vol. 59: 1-34 (1998).	
	SALAMON, et al. "Plasmon resonance studies of agonist/antagonist binding to the human δ -opioid receptor: New structural insights into receptor-ligand interactions", Biophysical Journal Vol. 79: 2463-2474 (2000).	
	SAMAMA, et al. "A mutation-induced activation state of the β_2 -adrenergic receptor", Journal of Biological Chemistry Vol. 268(7): 4625-4636 (1993).	
	SCHMIDT. "One-step affinity purification of bacterially produced proteins by means of the "Strep tag" and immobilized recombinant core streptavidin", Journal of Chromatography Vol. 676: 337-345 (1994).	
	SEIFERT, et al. "Reconstitution of β_2 -Adrenoceptor-GTP-Binding-Protein Interaction in SF9 Cells High Coupling efficiency in a β_2 -Adrenoceptor-G _{sα} Fusion Protein", Eur J. Biochem., 255: 369-382 (1998).	
	SELLEY, et al. " μ -Opioid receptor-stimulated guanosine-5'-O-(γ -thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy", Mol. Pharmacol. Vol. 51(1): 87-96 (1997).	
	SHEIKH, et al. "Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F", Nature Vol. 383: 347-350 (1996).	
	STAMMERS, et al. "Rapid purification and characterization of HIV-1 reverse transcriptase and RnaseH engineered to incorporate a C-terminal tripeptide α -tubulin epitope", FEBS Vol. 283: 298-302 (1991).	
	STRADER, et al. "Structure and function of G Protein-coupled receptors", Annu. Rev. Biochem. Vol. 63: 101-132 (1994).	
	STRANGE. "G-Protein coupled receptors", Biochem. Pharmacol. Vol. 58(7): 1081-1088 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/692,071		
		Filing Date	October 22, 2003		
		First Named Inventor	KOBILKA, BRIAN K.		
		Group Art Unit	1653		
		Examiner Name	Not Yet Assigned		
Sheet	5	of	5	Attorney Docket Number	STAN-213CIP

	STRANGE P. G. "Agonism and Inverse Agonism at Dopamine D ₂ -Like Receptors", Clinical and Experimental Pharm and Physio., 26 (Suppl) S3-S9 (1999).	
	SUBRAMANIAM, et al. "Molecular mechanism of vectorial proton translocation by bacteriorhodopsin", Nature Vol. 406: 653-657 (2000).	
	TOTA, et al. "Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system", Mol. Pharmacol. Vol. 37(6), 996-1004 (1990).	
	TUCEK. "Is the R and R* dichotomy real?", TIPS. Vol. 18(11): 414-416 (1997).	
	YANG, et al. "Structure and function in rhodopsin. Cysteines 65 and 316 are in proximity in a rhodopsin mutant as indicated by disulfide formation and interactions between attached spin labels", Biochem., (1996) Vol. 35: 14040-14046.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.